RenovoRx Publishes TIGeR-PaC Clinical Trial Abstract
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 26 2026
0mins
RenovoRx announced that an abstract from a pharmacokinetic and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial has been published online in connection with the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting on May 29 - June 2, 2026. The abstract, entitled "The TIGeR-PaC Phase 3 Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study," is a sub-study of the Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNXT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNXT
Wall Street analysts forecast RNXT stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.910
Low
3.00
Averages
5.63
High
12.50
Current: 0.910
Low
3.00
Averages
5.63
High
12.50
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RenovoRx Receives FDA Orphan Drug Designation for Oxaliplatin
- Orphan Drug Designation: RenovoRx announced that its oxaliplatin for pancreatic cancer has received FDA Orphan Drug Designation, marking the company's second designation in this area and highlighting its unique advantages in targeted drug delivery.
- Innovative Drug Delivery: The company employs its RenovoCath device for targeted intra-arterial drug delivery, having secured three orphan drug designations, which underscores its flexibility and innovation in delivering multiple therapeutic agents directly to tumor sites.
- Market Expansion: RenovoRx is advancing the commercialization of RenovoCath as a stand-alone device, aiming to drive adoption at leading cancer centers, thereby enhancing its competitive position in the market.
- Stock Price Movement: In Thursday's pre-market trading, RNXT was priced at $0.93, down $0.005 or 0.53%, reflecting a cautious market sentiment regarding the company's latest developments.
See More
RenovoRx Receives FDA Orphan Drug Designation
- FDA Orphan Drug Designation: RenovoRx has received Orphan Drug Designation from the FDA for oxaliplatin in treating pancreatic cancer, marking a significant recognition of the company's targeted drug delivery approach, which is expected to enhance its market competitiveness and investment appeal.
- Market Exclusivity Rights: Upon FDA approval of the indication, RenovoRx will enjoy seven years of market exclusivity, providing a stable revenue stream and strengthening its position in the oncology treatment market.
- Clinical Trial Progress: RenovoRx's TIGeR-PaC Phase III clinical trial is ongoing, with enrollment expected to close in June 2026 and final data readout anticipated in mid to late 2027, further validating its therapeutic efficacy.
- Sales Growth Potential: In 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, with a record $563,000 in the first quarter of 2026, indicating increasing market acceptance and future growth potential for its products.
See More
RenovoRx (RNXT) Q1 2026 Earnings Transcript
See More
RenovoRx CEO to Participate in Healthcare Showcase
- Commercial Progress Highlight: RenovoRx achieved record sales of $563,000 in Q1 2026 from RenovoCath as a standalone drug-delivery device, indicating strong demand and growth potential in the oncology market.
- Clinical Trial Advancement: The ongoing Phase III TIGeR-PaC trial is expected to complete enrollment by June 2026, providing critical data for evaluating the efficacy of the novel drug-device combination in locally advanced pancreatic cancer, which may drive future market applications.
- Research Support Initiatives: RenovoRx is actively supporting investigator-initiated trials for borderline resectable and metastatic pancreatic cancer, which not only provide valuable data for the TAMP therapy platform but also potentially broaden its clinical application and enhance market competitiveness.
- Showcase Participation: CEO Shaun Bagai and CFO Mark Voll will participate in the AGP Annual Healthcare Company Showcase on May 20, 2026, discussing the company's commercial progress and clinical research, which is expected to attract investor interest and enhance the company's visibility.
See More
RenovoRx Reports 136% Revenue Growth in Q1 2026
- Record Quarterly Revenue: RenovoRx achieved a record revenue of $563,000 in Q1 2026, representing a 136% increase compared to Q4 2025, indicating strong growth potential in the cancer treatment market.
- Expansion of Commercial Centers: The number of active commercial cancer centers increased from 8 at the end of 2025 to 16 by May 2026, demonstrating accelerated commercialization and a more diversified future revenue stream.
- Increased Investor Confidence: The company successfully closed an oversubscribed private placement, generating approximately $10 million in funding, reflecting strong market confidence and support for its future development.
- High R&D Expenses: Despite revenue growth, Q1 R&D expenses reached $1.2 million, indicating ongoing investment in technology development while also facing challenges in cost management.
See More
RenovoRx Q1 Earnings Report Analysis
- Earnings Performance: RenovoRx reported a Q1 GAAP EPS of -$0.09, missing expectations by $0.01, indicating challenges in profitability, while revenue reached $0.56 million, up 180% year-over-year, exceeding expectations by $0.1 million, suggesting improved market demand.
- Cash Flow Status: As of March 31, 2026, the company had approximately $12.4 million in cash and cash equivalents, indicating relatively healthy liquidity, and raised about $10 million in gross proceeds from a private placement in Q1, further strengthening its financial stability.
- Operational Funding Assurance: The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027, indicating a robust cash flow position that supports ongoing business development in the near term.
- Annual Revenue Guidance: RenovoRx reiterated its full-year 2026 revenue guidance of $3 to $4 million, reflecting confidence in future revenue growth despite profitability pressures, as the company actively seeks market opportunities.
See More
RenovoRx Receives FDA Orphan Drug Designation for Oxaliplatin
- Orphan Drug Designation: RenovoRx announced that its oxaliplatin for pancreatic cancer has received FDA Orphan Drug Designation, marking the company's second designation in this area and highlighting its unique advantages in targeted drug delivery.
- Innovative Drug Delivery: The company employs its RenovoCath device for targeted intra-arterial drug delivery, having secured three orphan drug designations, which underscores its flexibility and innovation in delivering multiple therapeutic agents directly to tumor sites.
- Market Expansion: RenovoRx is advancing the commercialization of RenovoCath as a stand-alone device, aiming to drive adoption at leading cancer centers, thereby enhancing its competitive position in the market.
- Stock Price Movement: In Thursday's pre-market trading, RNXT was priced at $0.93, down $0.005 or 0.53%, reflecting a cautious market sentiment regarding the company's latest developments.
See More
RenovoRx Receives FDA Orphan Drug Designation
- FDA Orphan Drug Designation: RenovoRx has received Orphan Drug Designation from the FDA for oxaliplatin in treating pancreatic cancer, marking a significant recognition of the company's targeted drug delivery approach, which is expected to enhance its market competitiveness and investment appeal.
- Market Exclusivity Rights: Upon FDA approval of the indication, RenovoRx will enjoy seven years of market exclusivity, providing a stable revenue stream and strengthening its position in the oncology treatment market.
- Clinical Trial Progress: RenovoRx's TIGeR-PaC Phase III clinical trial is ongoing, with enrollment expected to close in June 2026 and final data readout anticipated in mid to late 2027, further validating its therapeutic efficacy.
- Sales Growth Potential: In 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, with a record $563,000 in the first quarter of 2026, indicating increasing market acceptance and future growth potential for its products.
See More
RenovoRx (RNXT) Q1 2026 Earnings Transcript
See More
RenovoRx CEO to Participate in Healthcare Showcase
- Commercial Progress Highlight: RenovoRx achieved record sales of $563,000 in Q1 2026 from RenovoCath as a standalone drug-delivery device, indicating strong demand and growth potential in the oncology market.
- Clinical Trial Advancement: The ongoing Phase III TIGeR-PaC trial is expected to complete enrollment by June 2026, providing critical data for evaluating the efficacy of the novel drug-device combination in locally advanced pancreatic cancer, which may drive future market applications.
- Research Support Initiatives: RenovoRx is actively supporting investigator-initiated trials for borderline resectable and metastatic pancreatic cancer, which not only provide valuable data for the TAMP therapy platform but also potentially broaden its clinical application and enhance market competitiveness.
- Showcase Participation: CEO Shaun Bagai and CFO Mark Voll will participate in the AGP Annual Healthcare Company Showcase on May 20, 2026, discussing the company's commercial progress and clinical research, which is expected to attract investor interest and enhance the company's visibility.
See More
RenovoRx Reports 136% Revenue Growth in Q1 2026
- Record Quarterly Revenue: RenovoRx achieved a record revenue of $563,000 in Q1 2026, representing a 136% increase compared to Q4 2025, indicating strong growth potential in the cancer treatment market.
- Expansion of Commercial Centers: The number of active commercial cancer centers increased from 8 at the end of 2025 to 16 by May 2026, demonstrating accelerated commercialization and a more diversified future revenue stream.
- Increased Investor Confidence: The company successfully closed an oversubscribed private placement, generating approximately $10 million in funding, reflecting strong market confidence and support for its future development.
- High R&D Expenses: Despite revenue growth, Q1 R&D expenses reached $1.2 million, indicating ongoing investment in technology development while also facing challenges in cost management.
See More
RenovoRx Q1 Earnings Report Analysis
- Earnings Performance: RenovoRx reported a Q1 GAAP EPS of -$0.09, missing expectations by $0.01, indicating challenges in profitability, while revenue reached $0.56 million, up 180% year-over-year, exceeding expectations by $0.1 million, suggesting improved market demand.
- Cash Flow Status: As of March 31, 2026, the company had approximately $12.4 million in cash and cash equivalents, indicating relatively healthy liquidity, and raised about $10 million in gross proceeds from a private placement in Q1, further strengthening its financial stability.
- Operational Funding Assurance: The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027, indicating a robust cash flow position that supports ongoing business development in the near term.
- Annual Revenue Guidance: RenovoRx reiterated its full-year 2026 revenue guidance of $3 to $4 million, reflecting confidence in future revenue growth despite profitability pressures, as the company actively seeks market opportunities.
See More
